Nitrothienylprop-2-yl ether formation on the 3 ¶-phenolic position of combretastatin A-4 (1) abolishes the cytotoxicity and tubulin polymerization-inhibitory effects of the drug. 5-Nitrothiophene derivatives of 1 were synthesized following model kinetic studies with analogous coumarin derivatives, and of these, compound 13 represents a promising new lead in bioreductively targeted cytotoxic anticancer therapies. In this compound, optimized gemdimethyl A-carbon substitution enhances both the aerobic metabolic stability and the efficiency of hypoxia-mediated drug release. Only the gem-substituted derivative 13 released 1 under anoxia in either in vitro whole-cell experiments or supersomal suspensions. The rate of release of 1 from the radical anions of these prodrugs is enhanced by greater methyl substitution on the A-carbon. Cellular and supersomal studies showed that this A-substitution pattern controls the useful range of oxygen concentrations over which 1 can be effectively released by the prodrug. [Mol Cancer Ther 2006;5(11):2886 -94] 
Introduction
Combretastatin A-4 (CA4; 1; Fig. 1 ) is an antineoplastic and vascular targeting stilbene that was isolated from the South African bush willow tree Combretum caffrum (1 -4) . This new class of therapeutic compounds are known primarily as vascular targeting agents, which have potential use in disease conditions or pathologies, such as cancer, where an abnormal growth of blood vessels is an essential component to the disease and its progression (5) . The mechanism of action is through microtubule disruption, affecting the cytoskeleton of the endothelial cells lining the tumor vasculature (6 -8) . When this tubulin structure is disrupted, the endothelial cells change shape from flat to round, impeding blood flow through the capillary, starving the tumor of nutrients, and causing tumor cell death (8 -10) . Preclinical animal model studies and subsequent clinical trials have shown that the drug drastically reduces blood flow in tumors (11) . Phase I human cancer clinical trials of the sodium CA4 phosphate prodrug (2; Fig. 1 ) have been successfully completed (12, 13) and the drug is currently undergoing phase II trials.
The discovery of 1 prompted the synthesis of many structural variations as improved vascular targeting agents (14 -17) . However, the combretastatins also have powerful antiproliferative activity against cancer cell lines in vitro (3, 14, 18 -25) , and it is thought that this is due to an antimitotic action brought about by inhibition of tubulin polymerization. In contrast to the antivascular activity, this antimitotic activity requires prolonged exposure of the cells to the compounds. Therefore, it is probable that the latter activity is generally not expressed in vivo because rapid elimination of the compounds preclude this exposure at nontoxic doses. We have sought to exploit tumor hypoxia and examine whether combretastatin analogues delivered by a hypoxia-driven fragmentation strategy may offer the potential to deliver prolonged tumor exposure that may be antimitotic while minimizing host toxicity. This strategy may also, via a bystander effect, retain vascular targeting activity. It is thus the object of this study to synthesize and evaluate prodrugs that on bioreductive activation break down to release an antimitotic stilbene compound (i.e., CA4; 1; Fig. 2 ).
Although the phenolic 3 ¶-hydroxyl group of 1 is not essential for tubulin binding, large bulky groups in this region inhibit binding (9) . This position was therefore considered a good candidate for prodrug derivatization. Bioreductive targeting of phenolic compounds by indolequinones has been shown, and much work has been documented on the factors that control this process (26 -28) . Nitroaromatic compounds have also long been known to exhibit similar redox properties and have been studied as potential bioreductively activated prodrug delivery systems for a variety of drugs (29 -33) . However, despite the body of work about compounds that break down selectively under low oxygen tensions to release an anticancer agent, no such compound is yet in clinical use. Several problems have been encountered, including a lack of stability of the prodrugs toward nonbioreductive processes. Thus, carbonate-linked Taxol prodrugs were reported to be unstable toward enzymatic hydrolysis in cellular assays, thereby releasing Taxol by a nonreductive process (34) . Hypoxia-activated nitroheterocyclic phosphoramidates have also been reported, which were unstable in vivo, displaying rapid metabolism and consequent elimination half-lives of only a few minutes (35, 36) . Similarly, nitroheteroaryl quaternary salts have been synthesized as bioreductive prodrugs of mechlorethamine, but the compounds were too unstable with regard to nonspecific release of mechlorethamine to be of use as bioreductive agents (29, 30) . Thus, prodrugs showing improved stability toward nonreductive processes are desirable. A further consideration is the rate of release of the active drug under hypoxic conditions. To be effective, the bioreductively activated prodrug needs to deliver the drug at a rate that competes with clearance of the prodrug and diffusion of the drug out of the solid tumor. Prodrugs that fragment faster or that fragment more efficiently at oxygen tensions commonly found in solid tumors are desirable.
5-Nitrothiophenes have the required reduction potential to be of use in this respect (37, 38) , and we have sought to exploit this moiety for the reductive delivery of the phenolic stilbene 1 in this manner. We report herein the synthesis of combretastatin nitrothiophene ether-linked conjugates, optionally substituted on the a-carbon atom. Substitution at this position was carried out to facilitate manipulation of rates of reductive elimination and metabolic stability (39) . Initial compounds incorporated 7-hydroxy-4-methylcoumarin (3) as a model because of facile detection of its release in bioreductive conjugates (28) . The analogous CA4 derivatives were then synthesized for further chemical and biological evaluation.
Materials and Methods
Chemistry Nuclear magnetic resonance (NMR) spectra were obtained at 500 MHz using a Bruker AVC500, at 250 MHz using a Bruker AVC250, and at 60 MHz using a Jeol MY60 spectrometer with tetramethylsilane as internal standard. Melting points were obtained using an Electrothermal IA9100. High-resolution mass spectra (HRMS) on chromatographically homogeneous compounds were recorded on a VG Trio 2000 mass spectrometer. Elemental analyses were carried out by Medac Ltd., Brunel Science Centre, Egham, Surrey, United Kingdom. Silica gel for flash chromatography was Merck Kieselgel 60H grade (230 -400 mesh). High-performance liquid chromatography (HPLC)-mass spectrometry (MS) was done using a Waters Integrity System with electron effect ionization. Chromatography was carried out using a Hichrom (Theale, United Kingdom) RPB column (100 Â 3.2 mm) with eluents A: 5% acetonitrile, 0.1% trifluoroacetic acid (TFA); B: 100% acetonitrile; gradient 20% to 50% or 50% to 100% B, 4 minutes, or isocratically at 100% acetonitrile, at a flow rate of 0.5 mL/ min. Reverse-phase chromatography was conducted on Varian C18 Bond Elut straight barrel columns (sorbent mass, 1 g; volume, 6 mL; and particle size, 40 Am). Analytic TLC was done on precoated silica gel plates (60 F254, 0.2 mm thick, VWR). Visualization of the plates was accomplished using UV light and/or potassium permanganate staining. Solutions in organic solvents were dried by standard procedures, and dichloromethane, benzene, dimethylformamide, and tetrahydrofuran were anhydrous commercial grades. Solvents used for chromatography were HPLC grade and obtained from Sigma-Aldrich Chemical Co. 2-Bromomethyl-5-Nitrothiophene (5) (44) . Compound 4 (6.0 g, 38 mmol) was dissolved in dichloromethane (30 mL) and the solution was cooled to 0jC. Phosphorus tribromide (2.5 g, 50 mmol) in dichloromethane (30 mL) was then added dropwise and the solution was stirred for a further 0.5 hour. Dichloromethane (250 mL) was added and the solution was washed with water (2 Â 250 mL) and brine (100 mL), dried, and evaporated in vacuo. The product was used without further purification (6.0 g, 72%). 2-(1-Bromoethyl)-5-Nitrothiophene (7). Compound 6 (5.0 g, 29 mmol) was dissolved in dichloromethane (60 mL) and the solution was cooled to 0jC. Phosphorus tribromide (2.5 g, 50 mmol) in dichloromethane (5 mL) was then added dropwise and the solution was stirred for a further 2 hours. Dichloromethane (150 mL) was added and the solution was washed with water (2 Â 250 mL) and brine (100 mL), dried, and evaporated in vacuo. The residue was purified on silica (25% ethyl acetate/hexane) to give a yellow oil (4.0 g, 58%). 1 and the solution was cooled to 0jC. MeMgBr (3.0 mol/L in diethyl ether, 30 mL, 90 mmol) was then added via syringe under nitrogen. The solution was warmed to 20jC and stirring was continued for 3 hours. The solution was poured onto ice/water (25 g) and 0.1 mol/L HCl (250 mL) was added. The solution was extracted with diethyl ether (3 Â 70 mL), dried, and evaporated. The residue was purified on silica (20% ethyl acetate/hexane) and then a second silica column (dichloromethane) to give a colorless oil (3.5 g, 35%).
1 H NMR (60 MHz, CDCl 3 ) y 1.65 (s, 6H), 2.16 (s, 1H), 7.0 (m, 3H) ppm. LC-RT 3.09 minutes (TFA 50 -100%); MS (m/z, %) 142 (M + , 12), 124 (100), 109 (93). 2-(5-Nitrothien-2-yl)Propan-2-ol (9) (45). Compound 8 (3.0 g, 16 mmol) was dissolved in acetic anhydride (50 mL) and the solution was cooled to À70jC. Fuming nitric acid (1.2 mL, 20 mmol) was then added gradually with vigorous stirring. The solution was stirred for 1 hour at À70jC and then allowed to warm to À40jC and stirred for further 1 hour at this temperature. Ice/water (300 g) was then added and the slurry was stirred for 30 minutes before extracting with ethyl acetate (3 Â 75 mL). The organic layer was washed with sodium bicarbonate (saturated, 100 mL) and brine (50 mL), dried, and evaporated. The residue was purified on silica (20% ethyl acetate/hexane) to give an orange wax (1.5 g, 50%). . Compound 4 (500 mg, 3.14 mmol) was dissolved in tetrahydrofuran (5 mL) together with triphenylphosphine (1.68 g, 6.28 mmol) and 1 (1.98 g, 6.28 mmol). To this solution was added DEAD (1.09 g, 6.28 mmol) and the solution was heated at 50jC for 3 hours and evaporated to dryness and the residue was purified on silica (25% ethyl acetate/hexane) to give a pale yellow solid (mp 88 -90jC, 810 mg, 57%) after recrystallization from ethyl acetate/hexane. 1 (12) . DEAD (357 mg, 2.05 mmol) was added dropwise to a solution of alcohol 6 (55 mg, 0.32 mmol), 1 (648 mg, 2.05 mmol), triphenylphosphine (288 mg, 1.10 mmol), and tetrahydrofuran (3 mL). The reaction was stirred for 16 hours at ambient temperature and then partitioned (ethyl acetate and brine), aqueous phase extracted (ethyl acetate), organic phase washed (H 2 O and brine), dried (MgSO 4 ), and concentrated in vacuo. The residue was purified on silica (33% then 50% ethyl acetate/hexane and finally 100% ethyl acetate) to give a yellow oil (15 mg, 10%). 1-(4-Methoxy-3-(2-(5-Nitrothien-2-yl)Prop-2-Yloxy))-Phenyl-2-(3,4,5-Trimethoxy)Phenyl-Z-Ethene (13). 9 (200 mg, 1.07 mmol) was dissolved in benzene (2.5 mL) together with 1 (320 mg, 1 mmol) and ADDP (250 mg, 1 mmol) and the solution was maintained under argon with stirring. Tributylphosphine [200 mg, 1 mmol, dissolved in benzene (0.5 mL)] was then added via syringe and under argon. The solution was stirred for 24 hours at 20jC and then partitioned with ethyl acetate/water (100 mL) and the organic layer was washed with brine (50 mL), dried, and evaporated. The residue was purified on silica (33% ethyl acetate/hexane) and then on a second silica column (dichloromethane) to give a pale yellow oil (150 mg, 31%). 1 (4-Methylcoumarin-7-yl)Oxymethyl-5-Nitrothiophene (15). 3 (1.0 g, 5.68 mmol) was dissolved in chloroform (15 mL) together with silver (I) oxide (1.0 g, 4.24 mmol). 5 (1.0 g, 4.5 mmol) was then added in five portions over 6 hours, and the solution was stirred for a further 48 hours. The mixture was filtered, evaporated and then dissolved in a minimum amount of chloroform, and purified by column chromatography on silica (dichloromethane followed by a second column with 10% then 50% ethyl acetate/hexane) to give a yellow oil (13 mg, 4% 2-(1-(4-Methylcoumarin-7-yl)Oxy)Ethyl-5-Nitrothiophene (16). 3 (37 mg, 0.212 mmol) was dissolved in chloroform (1 mL) together with silver (I) oxide (50 mg, 0.212 mmol). 7 (50 mg, 0.212 mmol) was then added, and the solution was stirred for a further 48 hours. The mixture was filtered, evaporated, and then dissolved in a minimum amount of chloroform and purified by column chromatography on silica (dichloromethane followed by a second a column with dichloromethane) to give a pale yellow solid recrystallized from diethyl ether (15 mg, 21%, mp 146 -148jC 2-(1-Methyl-1-(4-Methylcoumarin-7-yl)Oxy)Ethyl-5-Nitrothiophene (17). 9 (187 mg, 1 mmol) was dissolved in tetrahydrofuran (2 mL) together with triphenylphosphine (472 mg, 1.8 mmol) and 3 (580 mg, 3.3 mmol). DEAD (574 mg, 3.3 mmol) was then added and the solution was heated at 105jC for 3.5 hours, cooled, and evaporated. The residue was dissolved in a minimum amount of acetone and purified by column chromatography on silica (dichloromethane followed by a second column with 25% ethyl acetate/hexane) to give a yellow oil. Ethyl 2-(4-Methylcoumarin-7-yl)Oxy-2-(5-Nitrothien-2-yl)Propanoate (18) . DEAD (100 mg, 0.57 mmol) was added dropwise to a solution of 10 (50 mg, 0.22 mmol), 3 (120 mg, 0.68 mmol), triphenylphosphine (100 mg, 0.38 mmol), and tetrahydrofuran (2 mL). The reaction was stirred for 72 hours and then concentrated in vacuo. The residue was dissolved in a minimum amount of acetone and purified by column chromatography on silica (dichloromethane followed by a second column with 25% ethyl acetate/ hexane) to give a yellow oil (10 mg, 11% Pulse Radiolysis Prodrug radicals were formed by reduction of the parent nitro compounds (typically 50 Amol/L) by the 2-propanol radical generated radiolytically in a N 2 O-saturated 2-propanol/water mixture (50% v/v) with 4 mmol/L potassium phosphate buffer (pH 7.4 -9). Experiments were done using a 6 MeV linear accelerator to generate an electron pulse (typically f500 ns) as described previously (46) . The absorbed radiation dose per electron pulse (typically 5 -35 Gy, equivalent to 3 -23 Amol/L reducing radicals) was determined by the thiocyanate dosimeter. Changes in absorbance were measured using a tungsten lamp and photodiode detector preceded by a single-pass monochromator.
Steady State ;-Radiolysis Prodrug solutions in 50% IPA/buffer (typically 40 Amol/L or below depending on solubility) were saturated with N 2 O in gas-tight syringes and then irradiated in a 60 Co HPLC HPLC analysis was done using a Waters 2695 separations module, Waters 2996 photodiode array detector, and Waters 474 fluorescence detector. Data were collected using Waters Millennium software. The column was a C18 Hichrom RPB (100 Â 3.2 mm) and the eluents were A: 10% acetonitrile, 90% water; B: 75% acetonitrile, 25% water. A gradient from 65% to 100% B was used over 3 minutes, with a 1-minute hold at 100%, and the flow rate was 1 mL/min. Detection was by absorbance at 292 nm (prodrugs) and by fluorescence (320 nm excitation and 390 nm emission; CA4).
Supersome Experiments Prodrugs were dissolved in DMSO to a concentration of 625 Amol/L, and 20 AL of this stock solution were added to a mixture of 60 AL Supersomal P450 reductase (P450R; Gentest, BD Biosciences, Oxford, United Kingdom), 20 AL NADPH (10 mmol/L), and 2.4 mL potassium phosphate buffer [250 mmol/L (pH 7.4)] to give a final prodrug concentration of 5 Amol/L and incubated at 37jC. For anoxic experiments, the mixture was degassed with N 2 for 20 minutes before prodrug addition and then overgassed with N 2 during incubation. Samples (100 AL) were added to acetonitrile (100 AL), mixed, and then centrifuged at 14,300 rpm for 2 minutes before HPLC analysis.
Later experiments, showing comparative release of CA4 (1) over a range of oxygen tensions, were carried out by dissolving prodrugs in DMSO to a concentration of 52 Amol/L, and 60 AL were added to a mixture of 10 AL Supersomal P450R, 10 AL NADPH (10 mmol/L), and 1.17 mL potassium phosphate buffer [250 mmol/L (pH 7.4)] to give a final prodrug concentration of 2.5 Amol/L and incubated at 37jC. Anoxic and hypoxic experimental mixtures were degassed with either N 2 , 0.02%, 0.04%, 0.06%, 0.1%, 0.2%, 0.3%, 0.5%, 1%, 2%, or 5% O 2 , or air for 20 minutes before prodrug addition and then overgassed with the appropriate gas during incubation. Samples (100 AL) were added to acetonitrile (80 AL), mixed, and then centrifuged at 14,300 rpm for 2 minutes before HPLC analysis. The oxygen content in the samples was measured using an Oxy Lab fitted with an oxygen-monitoring probe (Oxford Optronix, Oxford, United Kingdom).
A549 Whole-Cell Experiments
Prodrugs were dissolved in DMSO to a concentration of 625 Amol/L, and 80 AL were added to 10 mL A549 cells in Eagle's MEM (f10 6 cells/mL) to give a final prodrug concentration of 5 Amol/L and incubated at 37jC. For anoxic experiments, the mixture was degassed with N 2 + 5% CO 2 for 30 minutes before prodrug addition and then overgassed with N 2 during incubation. Hypoxic experimental mixtures were degassed with either 0.1% or 0.3% O 2 (5% CO 2 , balance N 2 ) for 30 minutes before prodrug addition and then overgassed with the appropriate gas during incubation. Samples (1 mL) were added to 100 mmol/L hydrochloric acid (0.2 mL), mixed, and then extracted (via solid-phase extraction) before HPLC analysis.
Liver Metabolism Metabolism of 5 Amol prodrug in air was done with 0.5 mL mouse liver homogenate [4 mg protein (Bradford assay)] with 100 Amol/L NADPH in 50 Amol/L potassium phosphate buffer at pH 7.4 incubated at 37jC. Samples were taken at regular intervals, added to an equivalent volume of acetonitrile, mixed, and centrifuged at 14,300 rpm for 2 minutes before HPLC analysis.
Tubulin Binding A tubulin binding assay kit (Totam Biologicals Ltd., Peterborough, United Kingdom) was used to determine the relative binding efficiencies of the prodrugs. Composition A (100 AL) was added to a vial containing 250 Ag bovine tubulin protein and either 2 AL DMSO for control or 2 AL of the appropriate concentration of drug in DMSO. The sample was mixed well and transferred to a spectrophotometer cuvette in a cell holder previously equilibrated at 37jC and the absorbance was read immediately at 340 nm. Absorbance readings were continued at 2-minute intervals for 1 hour.
Results and Discussion
The primary and secondary 5-nitrothienyl alcohols, 4 and 6, were prepared by sodium borohydride reduction of commercially available 5-nitrothiophene-2-carboxaldehyde and 2-acetyl-5-nitrothiophene, respectively (Fig. 3) . Preparation of the gem-dimethylalcohol 9 involved Grignard addition of methylmagnesium bromide to 2-acetylthiophene and then careful nitration of the intermediate tertiary alcohol 8 with fuming nitric acid and acetic anhydride. a-Hydroxy ester 10 was synthesized via a vicarious nucleophilic substitution reaction as described by Lawrence et al. (43) .
Two different sets of Mitsunobu conditions (47) were used to couple the alcohols to stilbene 1 (Fig. 4) . The more commonly used reagent mixture of DEAD (or DIAD)/ triphenylphosphine was used to synthesize primary and secondary alkyl-aryl ethers, 11 and 12. Surprisingly, etherification of the hindered a-hydroxy ester 14 was effected using the same conditions, whereas a combination of ADDP/tributylphosphine was necessary for successful preparation of the hindered tertiary alkyl-aryl ether, 13. Synthesis of the analogous coumarins (Fig. 4) was carried out in the same manner or by treating the bromides 5 and 7, Figure 5 . CA4 (1) production in P450R supersomes under air (A) and anoxia (B). Prodrugs were dissolved in DMSO to a concentration of 625 Amol/L, and 20 AL were added to a mixture of 60 AL Supersomal P450R (Gentest), 20 AL NADPH (10 mmol/L), and 2.4 mL potassium phosphate buffer (pH 7.4) to give a final prodrug concentration of 5 Amol/L and incubated at 37jC. For anoxic experiments, the mixture was degassed with N 2 for 20 min before prodrug addition and then overgassed with N 2 during incubation. Samples (100 AL) were added to acetonitrile (100 AL), mixed, and then centrifuged at 14,300 rpm for 2 min before HPLC analysis. Points, single observation at each time. Figure 6 . Prodrug metabolism in oxic liver homogenates. Metabolism of 5 Amol prodrug in air was done with 0.5 mL mouse liver homogenate (f4 mg protein by the Bradford assay) with 100 Amol/L NADPH in 50 mmol/L potassium phosphate buffer at pH 7.4 incubated at 37jC. Samples were taken at regular intervals, added to an equivalent volume of acetonitrile, mixed, and then centrifuged at 14,300 rpm for 2 min before HPLC analysis. Points, single observation at each time.
synthesized by phosphorus tribromide bromination of the alcohols, with silver (I) oxide and 7-hydroxy-4-methylcoumarin (3) .
Bioreductive activation of prodrugs may involve obligate one-electron donors, typically flavoproteins, such as NADPH:cytochrome P450R, or two-electron reduction, typically diaphorases, such as NQ01. In the present work, we have emulated reduction by one-electron processes in the hypoxic environments of solid tumors, and the inhibition of this process in the normoxic environments of normal tissues, by generating prodrug radical anions radiolytically. This enables us to evaluate the relative abilities of bioreductively activated prodrugs to release the active drug after one-electron reduction. Pulse radiolysis with spectrophotometric detection allows the generation and monitoring of the prodrug radical (Eqs. 1 -4) in microseconds and subsequent radical fragmentation or reaction with O 2 , usually in milliseconds.
where ArNO 2 À is the prodrug radical anion. 3 per well on a 96-well plate and allowed to attach for 24 h. Compounds were dissolved in DMSO and diluted with cell culture medium before addition. The cells were exposed to test compound (0 -2 Amol/L) for 6 h and then incubated for a further 72 h. Viable cells were determined using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega Corp., Southampton, United Kingdom). Points, mean of eight wells of one experiment. Table 1 shows radical anion half-lives of conjugates of nitrothiophenes with both CA4 (1) and coumarin derivatives. The data clearly show that geminal a-dimethyl substitution increases both the rate and the efficiency of reductive elimination from reduced nitrothiophenes, with a 10-fold decrease in radical half-life for the a-gemsubstituted CA4 conjugate compared with its a-monosubstituted analogue. The related coumarin derivatives exhibited a similar, although more pronounced trend, with relative half-lives of 850:45:1 for the series, a-unsubstituted, a-methyl, and a-gem-dimethyl. The efficiency of reductive elimination (fragmentation efficiency) was also increased by geminal substitution within this series.
The selection of 13 over the related lesser-substituted prodrugs was supported following studies of reduction by cytochrome P450R supersomes (Fig. 5) . These data show that 1 is selectively produced by 13 in P450R supersomes under anoxia, whereas 11 and 12 were ineffective in this respect.
In oxic liver homogenates, 13 was metabolically stable over an incubation period of 16 hours, whereas the other, lesser-substituted analogues 11 and 12 were not. These data are presented in Fig. 6 and suggest that such substitution has also successfully inhibited undesired aerobic metabolism, which was suffered by 11 and 12 during this incubation period. Benzylic ethers, with at least one hydrogen atom on the a-carbon, are prone to oxidation in oxic liver metabolites to give the corresponding carbonyl compound (i.e., an ester), which can then be cleaved by cellular esterases thus producing 1. Compound 13 was also stable when incubated in aerobic A549 whole-cell suspensions but released 1 efficiently under anoxic conditions (Fig. 7) . The efficiency of this drug release in supersomal suspensions over a range of clinically relevant oxygen concentrations was determined and the results are presented in Fig. 8 . The radiolysis studies with the coumarin model prodrugs 15 to 18 showed the fragmentation rate-enhancing effect of a-substitution. Fragmentation is expected to be in competition with the reversal of reduction by oxygen (Eq. 5).
This suggests that such substitution might extend the range of oxygenation status within the cells that could be targeted. It was thus predicted, based on these model studies, that the geminally substituted 13 would exhibit the broadest range of oxygen tensions that could be targeted, and Fig. 8 does indeed indicate that significant CA4 release was achieved up to a 0.3% oxygen concentration in A549 cells with this compound. The range of oxygen concentrations over which CA4 was released in supersomal suspensions by compounds 11 to 13 is shown in Fig. 9 . The unsubstituted analogue 11 only released CA4 over a narrow range of low oxygen concentrations (<0.01% O 2 ) with complete inhibition above this level. The monosubstituted (12) and geminal (13)-substituted compounds, on the other hand, efficiently released the drug over a much broader range of oxygen concentrations, with 13 being >50% inhibited (compared with N 2 ) only above 0.5% O 2 .
The prodrug 13 did not inhibit the growth of A549 cells up to concentrations of 2 Amol/L (Fig. 10) and similarly had no effect on tubulin polymerization (Fig. 11) , further showing the prodrug status of the compound and the successful masking of the activity of 1 through ether linkage to a nitrothiophene moiety.
In conclusion, the presence of two a-substituents bestows beneficial properties on the compounds by inhibiting aerobic metabolism. The increased steric bulk provided by these substituents may thus stabilize the compounds against release of the cytotoxic or cytostatic drug moiety by chemical or enzymatic processes other than the desired bioreductive processes. Furthermore, the absence of a hydrogen atom a to the aromatic group is likely to prevent metabolic oxidation at this position, which can lead to release of the effector outside hypoxic regions. The electronic effects of substituents R 1 and R 2 clearly enhance the rate of reductive elimination and leads to an extended range of hypoxic oxygen tensions at which the cytotoxic or cytostatic moiety is released (up to 1% oxygen for compound 13). This may ultimately provide effective and selective delivery of the cytotoxic or cytostatic compound to a solid tumor.
